ANAVEX2-73-RS-003 is a Phase 2/3, double-blind, randomized, placebo-controlled dose escalation safety, tolerability and efficacy study in patients 5-17 years of age with RTT using endpoints including multiple clinical and exploratory molecular and biochemical measures.

开始日期2020-07-01

申办/合作机构

Anavex Life Sciences Corp.

[+2]

NCT04314934

/ Completed临床2/3期

Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004

This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.

开始日期2019-10-10

申办/合作机构

Anavex Life Sciences Corp.

[+2]

NCT04575259

/ Completed临床2期

Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.

开始日期2019-10-10

申办/合作机构

Anavex Life Sciences Corp.

[+2]

100 项与 Blarcamesine 相关的临床结果

登录后查看更多信息

100 项与 Blarcamesine 相关的转化医学

登录后查看更多信息

100 项与 Blarcamesine 相关的专利（医药）

登录后查看更多信息

项与 Blarcamesine 相关的文献（医药）

2026-04-01·EUROPEAN NEUROPSYCHOPHARMACOLOGY

Emerging neurobiological targets in psychiatric treatment

Review

作者: Berk, Michael ; Govinnage, Janani ; Giorlando, Frank ; De Zoysa, Agampodi Ishan ; Narayanaswamy, J C ; Dodd, Seetal

Despite significant advancements in psychopharmacology, there are inadequate treatment options for many psychiatric disorders, including major depressive disorder, bipolar disorder, schizophrenia, and anxiety disorders. This review explores emerging neurobiological targets beyond conventional monoaminergic approaches, focusing on sodium channels, Neuropeptide Y (NPY), Neurokinin 1 (NK1) receptors, P2 × 7 purinergic receptors, Sigma-1 receptors, and Orexin. Recent evidence suggests that sodium channel modulators, such as evenamide, may offer therapeutic benefits for treatment-resistant schizophrenia by stabilizing glutamatergic neurotransmission. NPY-based therapies have potential in stress-related disorders, foreshadowing rapid anxiolytic and antidepressant effects through modulation of the stress response. NK1 receptor antagonists, although inconsistent in mood disorders, show promise in addiction treatment by reducing substance cravings. The P2 × 7 receptor, a key regulator of neuroinflammation, has been implicated in mood disorders, and its pharmacological inhibition may provide neuroprotective benefits. Additionally, Sigma-1 receptor agonists, including Blarcamesine and Pridopidine, have shown neuroprotective and cognitive-enhancing properties, making them attractive candidates for psychiatric and neurodegenerative disorders. Orexin receptor antagonists, such as suvorexant and seltorexant, have potential in mood disorders and substance dependence, highlighting the broader therapeutic applications of targeting the orexinergic system. While these emerging therapeutic targets hold promise, challenges remain in translating preclinical findings into effective clinical applications. Large-scale, placebo-controlled trials are necessary to establish their efficacy and safety. The identification of biomarkers for patient stratification will be critical in the hitherto elusive goal of developing precision medicine approaches. Targeted pharmacological interventions offer a path toward more effective, well-tolerated, and potentially individualized treatment options for patients with severe mental illness.

2025-12-01·Alzheimers & Dementia

Precision Medicine in Alzheimer’s Disease (AD): Observed Efficacy Treatment Effects from Blarcamesine Clinical AD Trials

Article

作者: Gueddou, Ayoub ; Courreges, Olivier ; Missling, Christopher U ; Guizard, Nicolas ; Lopez‐Talavera, Juan Carlos ; Sabbagh, Marwan N. ; Villa, Luca ; Gabelle, Audrey ; Jin, Kun ; Gordon, Elizabeth ; Chezem, William R. ; Grimmer, Timo ; Borrot, Mathilde

Abstract:

Background:

Precision Medicine represents a transformative approach in treating Alzheimer’s disease (AD), focusing on tailoring interventions based on individual genetic, molecular, clinical and environmental profiles in addition to confirm clear Mechanism of Action (MoA). This strategy aims to optimize treatment outcomes by identifying patient subgroups that are most likely to benefit or benefit at a higher degree from specific therapies, thus reducing inefficacies and potentially adverse effects associated with generalized treatment regimens.

Method:

Blarcamesine, a selective modulator of the Sigma‐1 receptor (SIGMAR1), has garnered attention due to its role in autophagy, cellular stress response, protein homeostasis, and neuroprotection. Recent clinical studies have confirmed its effects in the majority of AD patients who carry the homozygous wild‐type (WT) SIGMAR1 genotype (∼70% of the whole population) (Hampel et al., 2020).

Result:

In the Phase IIb/III ANAVEX2‐73‐AD‐004 trial, a clear MoA of oral once daily blarcamesine, a pre‐specified efficacy analysis confirmed the importance of SIGMAR1 to clinical response. While all trial participants improved significantly versus placebo after 48 Weeks, 36.3% for ADAS‐Cog13 and 27.6% for CDR‐SB, respectively, a further, also significant, improvement was observed in the prespecified analysis of SIGMAR1 carriers. Compared to the ITT group, participants carrying the SIGMAR1 WT gene observed further improvement versus placebo of 49.8% and 33.7% for the primary and secondary key endpoints ADAS‐Cog13 and CDR‐SB, respectively (Macfarlane et al., 2025).

Conclusion:

Thus, the specificity of blarcamesine to this genotype underscores the importance of understanding clear MoA and potential for further improved personalized medicine in AD treatment, as therapies targeting individual molecular profiles could achieve more substantial and sustained benefits. While Precision Medicine holds great promise for improving the treatment paradigm of AD by offering more personalized, likely more effective therapies, it also introduces challenges related to potential cost, data privacy, ethical concerns, and inequities in access. Addressing these issues is crucial to ensure that the benefits of Precision Medicine can be realized for all patients.

2025-12-01·Alzheimers & Dementia

Phase IIb/III ATTENTION‐AD Study: Over Three Years of Continuous Treatment with Oral Blarcamesine Continues to Significantly Benefit Early Alzheimer’s Disease Patients

Article

作者: Sabbagh, Marwan N. ; Chezem, William R. ; Gabelle, Audrey ; Jin, Kun ; Macfarlane, Stephen ; Lopez‐Talavera, Juan Carlos ; Grimmer, Timo ; Missling, Christopher U

Abstract:

Background:

There are no approved oral disease‐modifying small molecule therapies for treatment of early Alzheimer’s disease (AD). Blarcamesine is an orally bioavailable small molecule that enhances autophagy through SIGMAR1 activation and restoration of cellular homeostasis in early AD.

Method:

The ATTENTION‐AD study was an up to 144‐week open‐label extension study subsequent the 48‐Week Phase IIb/III double‐blind placebo‐controlled ANAVEX ® 2‐73‐AD‐004 study, to evaluate the safety and efficacy of oral once daily blarcamesine in 508 participants with early AD. Delayed‐start analysis was performed to assess the effect of early treatment initiation up to 192 Weeks.

Result:

The ATTENTION‐AD trial confirmed the good efficacy and safety profile of once daily oral blarcamesine and also demonstrated the manageable nature of the most frequent treatment emergent adverse event (TEAE) (dizziness) observed in the preceding ANAVEX ® 2‐73‐AD‐004 trial, which was generally transient in duration (approx. 7‐11 days) and mild or moderate in severity (Grade 1 or 2). The titration schedule was adjusted to a slightly longer titration period in the ATTENTION‐AD trial, from previous 2‐3 weeks to 10 weeks. A markedly lower frequency of the TEAE of dizziness in the respective maintenance phase was observed: from previously 25.2% in the ANAVEX ® 2‐73‐AD‐004 trial to 9.6% in the ATTENTION‐AD trial, demonstrating the manageable nature of this TEAE. No severe or life‐threatening adverse events were attributed to blarcamesine. No Amyloid Related Imaging Abnormalities (ARIA) adverse events were identified. There were no deaths related to blarcamesine. Efficacy of the cognitive and functional endpoints in the delayed‐start analysis of treatment resulted in significant outcomes, ADAS‐Cog13 (LS mean difference ‐3.83, P = 0.0165) and ADCS‐ADL (LS mean difference +4.30, P = 0.0206) at Week 192, reflecting importance of early treatment initiation with oral blarcamesine.

Conclusion:

Blarcamesine significantly reduced clinical decline showing meaningful benefit for early Alzheimer’s disease patients. Blarcamesine exhibited a favorable safety profile with no treatment‐related deaths and demonstrated no associated neuroimaging adverse events with continued treatment over 4 years. Altogether, these results indicate that blarcamesine may be an effective, safe, and novel scalable oral treatment for early AD.

167

项与 Blarcamesine 相关的新闻（医药）

2026-02-25

·今日头条

阿尔茨海默病2026治疗突破：多款新药进展，早期患者可延缓衰退超三年

> 长期以来，阿尔茨海默病（AD）的治疗局限于缓解症状，无法阻止认知功能的持续衰退。但2026年，随着多款新药在临床试验中取得关键进展，治疗格局正迎来根本性转变。从给药方式的革新到作用机制的多元化，这些突破为早期患者带来了延缓疾病、保留生活质量的现实希望。 ![](blockview://markdown-image-tos-cn-i-tt/92cf722a5d794275af1e35871c525104) ## 从医院到家庭：仑卡奈单抗皮下注射剂型获优先审评作为首个针对β淀粉样蛋白原纤维的生物制剂，仑卡奈单抗（Leqembi）的静脉剂型已于2024年在中国获批。但其每两周一次的医院输液要求，给患者和照护者带来不便。2026年，这一痛点有望解决。 - **皮下注射剂型已获得美国FDA和中国国家药监局的优先审评资格**。美国FDA的最终决定预计于**2026年5月24日**做出。 - 如果获批，患者可使用自动注射器居家每周给药一次，每次注射约**15秒**。 - 数据显示，皮下注射与静脉输液的疗效和安全性相当，全身性注射反应发生率低于**2%**。静脉剂型的疗效已有数据支持：治疗**18个月**可降低临床进展风险**27%**。国内临床应用显示，用药18个月后，**60%**的早期患者实现了病情逆转。皮下剂型的推出，将大幅提升治疗可及性和患者依从性。 ## 口服药崛起：Blarcamesine延缓认知衰退超三年 ![](blockview://markdown-image-tos-cn-i-tt/234ff32ab4344434a267b6c64092abaf) 口服给药是提高长期治疗依从性的关键。Blarcamesine（ANAVEX2-73）作为一种口服小分子药物，正在**II/III期临床试验**中。 - 2025年公布的ANAVEX2-73-AD-004研究显示，治疗48周时，患者的认知能力减退被延缓了**36.3%**，功能减退被延缓了**27.6%**。 - 这相当于为早期患者争取了**超过三年的高质量生活期**，在此期间可能保留记忆、自理和情感交流能力。其作用机制通过激活sigma-1受体，增强细胞清除毒性蛋白的能力，并从上游调控线粒体功能和神经炎症。长期随访数据显示，药物对记忆、语言、定向力、生活自理四项核心能力均有稳定保护作用。 ## 靶向tau蛋白：Valiltramiprosate降低关键病理水平除了淀粉样蛋白，tau蛋白的异常磷酸化是AD的另一核心病理。Valiltramiprosate（ALZ-801）直接靶向这一过程。 - 在轻度认知障碍（MCI）患者中，治疗组的关键病理蛋白**p-tau217水平下降约36%**，而安慰剂组上升17%。 - 这一差异**直接转化为认知功能的获益**，计划于**2026年启动新的III期研究**。这标志着治疗策略向多靶点延伸，为不同病理特征的患者提供个性化选择。 ## 填补空白：ML-007C-MA瞄准精神症状约**40%**的AD患者会出现幻觉、妄想等精神症状，但目前全球尚无获批的针对性药物。ML-007C-MA有望填补这一空白。 - 作为新型M1/M4毒蕈碱受体激动剂，它已获**FDA快速通道资格**，专门用于治疗AD伴发的精神症状。 - II期VISTA研究正在进行中，顶线结果预计将于**2026年第三季度**公布。如果成功，这将不仅改善患者的生活质量，也显著减轻照护者的负担。 ## 未来技术：CAR-T细胞疗法跨界挑战脑部疾病源自癌症治疗的CAR-T细胞疗法，正被探索用于神经退行性疾病。2026年2月发表的研究显示，工程化的CAR-T细胞能有效减少小鼠脑内的淀粉样沉积，并降低神经炎症。 ![](blockview://markdown-image-tos-cn-i-tt/de68d222efa14ac5a93c0d600f22240f) - 研究团队使用**CD4+T细胞**而非细胞毒性的CD8+T细胞，以避免神经元损伤。 - 通过**mRNA技术**构建的临时性CAR-T细胞，展现了更强的治疗潜力，能深入脑实质清除斑块。虽然距离临床应用尚远，但这项技术为AD乃至其他脑部疾病开辟了全新的治疗路径。 ## 表观遗传新靶点：FLAV-27恢复小鼠记忆表观遗传调控是AD研究的新前沿。首创的SAM竞争性G9a抑制剂FLAV-27，在临床前模型中表现出色。 - 在AD小鼠模型中，口服FLAV-27能显著改善在新物体识别等测试中的**记忆表现**，增加树突棘密度，并降低Aβ负荷与神经炎症。 ![](blockview://markdown-image-tos-cn-i-tt/01aea6b6fd0c4a8ab9d55d555499de26) - 它具有优异的血脑屏障穿透能力，**脑/血浆比达3–6:1**，且安全性良好。这为通过表观遗传重编程治疗AD提供了概念验证，目前正进入人体临床试验阶段。 ## 总结与展望：早诊断早干预是关键 2026年的进展显示，AD治疗正从单一靶点向多机制协同演进： - **治疗更便捷**：从静脉输液到居家皮下注射。 - **靶点更多元**：涵盖淀粉样蛋白、tau蛋白、神经炎症、精神症状乃至表观遗传。 - **技术更前沿**：CAR-T等活细胞疗法开始探索神经退行性疾病领域。 > 所有新疗法主要针对早期阿尔茨海默病或轻度认知障碍阶段患者，这再次强调了早筛查、早诊断、早干预的极端重要性。当家人出现持续记忆力下降、判断力减退或性格改变时，应及时前往神经内科或记忆门诊就诊。尽管根治仍待时日，但多款新药的并行突破，正将“不治之症”推向“可管之病”的新时代。

2026-02-24

·AD新药研究与试验发展

2026速览：“能治本”的阿尔茨海默病疗法研究进展

一、清除大脑淀粉样蛋白的疗法近年来，美国食品药品监督管理局（FDA）已批准两种可清除脑内毒性β‑淀粉样蛋白的治疗药物：仑卡奈单抗（Leqembi，lecanemab）与多奈单抗（Kisunla，donanemab）。二者均被证实可延缓早期阿尔茨海默病患者的认知功能衰退。此类药物并非仅对症治疗，而是可直接让疾病病理进程“刹车”。仑卡奈单抗与多奈单抗作为“能治本”的病程修正治疗领域的首批药物，具备阻断阿尔茨海默病疾病进展的潜在作用。目前相关研究仍在持续开展，旨在进一步优化上述药物并降低不良反应，重点关注淀粉样蛋白相关影像学异常（ARIA），包括微出血、脑水肿等。仑卡奈单抗与多奈单抗的生产企业正与FDA合作开展临床研究，优化给药剂量与给药方案，以实现获益最大化与不良反应风险最小化。近期重要进展为：仑卡奈单抗居家注射剂型获FDA批准。该批准具有里程碑意义，可使接受仑卡奈单抗治疗的患者实现居家自行皮下注射给药，无需前往医疗机构静脉输注。该剂型在提升便捷性的同时，可显著降低阿尔茨海默病患者及其照护者的治疗壁垒，扩大治疗可及性。当前居家注射剂型（皮下注射）仅限已经在医院接受仑卡奈单抗静脉输注治疗的患者维持治疗使用；FDA预计于2026年5月就是否批准起始剂量即可居家使用作出审批决定。二、下一代清除淀粉样蛋白的新药尽管已有两种“能治本”的病程修正药物获批上市，但是研究者仍在开发靶向淀粉样斑块的新一代治疗药物，其中特罗替奈单抗（trontinemab）已进入Ⅲ期临床试验。静脉输注给药所面临的关键挑战是如何使药物通过血脑屏障进入大脑的问题。特罗替奈单抗（暂译）采用罗氏公司专有的Brainshuttle™（脑穿梭）递送技术，提升脑内递送效率，进而实现淀粉样斑块清除。早期临床试验显示，经28周治疗后，92%受试者脑内未检出可测量的斑块，且ARIA不良反应发生率较低。两项Ⅲ期临床试验（TRONTIER 1与TRONTIER 2）正在进行中，预计2028年公布结果。三、能“治本”的阿尔茨海默病口服新药研发现有治疗均需静脉输注或注射给药。研究者正致力于开发口服给药制剂，有效口服药物的问世将成为突破性进展，显著简化治疗流程并提升可及性。 Blarcamesine（暂译：布拉卡梅辛）是一款针对阿尔茨海默病等神经退行性疾病的在研小分子药物，由Anavex Life Sciences研发，其研发代号为AVEX101。目前处于Ⅱ/Ⅲ期临床试验，其作用机制不同于前述淀粉样蛋白清除抗体，该药不直接靶向淀粉样蛋白，而是通过激活σ‑1受体调控细胞内蛋白清除系统，进而增强神经元对淀粉样斑块的清除能力。其早期安全性与有效性数据积极，目前正在开展Ⅱ/Ⅲ期临床评价。 ALZ‑801为领域内备受关注的口服在研小分子药物，其作用于毒性淀粉样蛋白生成的上游环节，以抑制神经原纤维缠结形成为治疗目标。近期完成的Ⅲ期临床试验（APOLLOE4）纳入携带双拷贝的阿尔茨海默病风险基因APOE4的早期阿尔茨海默病患者。约10%接受ALZ‑801治疗的受试者表现出认知功能改善，此类对治疗产生良好效果的超级应答者多为年轻的、病程更短的患者，提示该药物可能使携带双拷贝APOE4风险基因的特定人群产生“治本”的临床效果。 ALZ‑801是基于tramiprostate（暂译：曲米前列腺素）而研发的，是由BrightFocus基金会百年资助项目获得者Donald Weaver博士共同开发。该基金支持阿尔茨海默病小分子药物发现研究。四、阿尔茨海默病非药物治疗 2024年末，Sinaptica Therapeutics公司开展的Ⅱ期临床试验显示：个体化无创脑刺激可使轻中度阿尔茨海默病患者认知衰退速度减缓44%，并改善行为症状、维持日常生活能力。该疗法正在开展进一步临床试验验证。该公司联合创始人Giacocco Koch医学博士、哲学博士获得BrightFocus基金会阿尔茨海默病研究项目资助，推动该技术完成人体临床试验。 Annabelle Singer博士正在开展脑刺激相关研究，评估其降低脑内应激反应、减少阿尔茨海默病发病风险的作用；同时探索高频闪光刺激对脑内记忆存储机制的影响。Cognito Therapeutics公司资助的早期临床试验初步结果提示，频率为40 赫兹左右的光声同步刺激可延缓认知衰退与脑容积丢失，该技术目前正在开展Ⅲ期临床试验。另一项具有变革潜力的无创技术为聚焦超声波。通过高频声波可暂时性、可逆性地开放血脑屏障，显著提升抗淀粉样蛋白抗体等治疗药物的脑内递送效率，同时促进脑内生物标志物释放入外周血以便检测。目前两项由阿尔茨海默病研究项目与聚焦超声基金会联合资助的研究正在探索该技术在阿尔茨海默病中的治疗价值：Isabelle Aubert博士研究超声是否可促进髓鞘生成细胞再生；Nader Saffari博士团队探索超声激活脑内小胶质细胞、加速毒性淀粉样斑块清除的作用。五、阿尔茨海默病风险防控治疗仅为防控体系的一部分。相关研究同时探索通过生活方式干预等手段延缓甚至预防认知衰退的策略。美国POINTER研究结果证实，生活方式综合干预可显著改善认知衰退高危老年人群的认知健康。干预方案包括：规律运动、优化营养、认知与社交活动参与、心血管及代谢健康监测。六、未来展望 2026年阿尔茨海默病治疗格局呈多元化发展，多款口服药物处于临床试验阶段，非淀粉样蛋白通路亦成为可行干预靶点。同时，治疗时间窗持续前移。具有里程碑意义的AHEAD研究正在对无症状高风险人群早期使用仑卡奈单抗的效果进行评估，探索在症状出现前阻断阿尔茨海默病发生的策略。新一代阿尔茨海默病治疗药物的研发与转化有赖持续科研支持。得益于更多志愿者（患者）的支持，阿尔茨海默病研究项目已资助全球数百位研究者开展创新性研究。信息来源 https://www.brightfocus.org/resource/expanding-the-alzheimers-treatment-landscape-a-2026-forecast/ 免责申明本微信公众号aarmednews为神经科学专业信息分享平台。因采编和专业学术水平有限，所发布信息仅供读者阅读参考，不作为任何实践指导和决策。本公众号不对任何主体因使用本文内容而导致的任何损失承担责任。发布内容和部分图片引自网络和科学研究文献，均注明来源。如仍有涉及版权保护问题，请及时联系本公众号删除。原创文字属于本公众号，转发请注明出处。

临床3期加速审批申请上市

2026-02-23

·BioSpace

Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Dr. Axel Paeger, MD, MBA, MBI to its Board of Directors. “We are delighted to welcome Dr. Paeger to our Board of Directors at Anavex,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “Dr. Paeger brings three decades of strong leadership experience in the healthcare industry, offering invaluable guidance as we continue to advance Anavex’s mission of developing new medicines for the treatment of neurological disorders and progress our innovative pipeline. His extensive knowledge of patient care will be instrumental in shaping Anavex’s strategic evolution with a focus on progressing our late-stage candidates and bringing potential new therapies to people living with CNS disorders.” Dr. Paeger is a seasoned leader in healthcare with over 30 years of experience in running inpatient medical care. Dr. Paeger currently serves as Chief Executive Officer of the AMEOS Group, headquartered in Zürich, Switzerland, which is today among the leading healthcare providers in Europe. The AMEOS Group owns and runs 85 hospitals and polyclinics and additionally 23 long-term elderly care and long-term mental care facilities. 19,300 employees serve about half a million patients per year. While the AMEOS Group generates about one third of its revenues from its psychiatric hospitals, it is the market leader in psychiatric inpatient care in the DACH (Germany, Austria, Switzerland) region, a region in Europe with a combined GDP approaching $6 trillion. The AMEOS Group is also a major provider of inpatient neurological care. Dr. Paeger started his career as hospital manager subsequent to gaining several years of clinical medicine experience in hospitals. He worked for Pacific Health, Inc. in the U.S. and for Asklepios Kliniken GmbH in Germany, before founding AMEOS as a start-up company in 2002. The AMEOS Group is today among the leading healthcare providers in Europe. Dr. Paeger holds degrees in medicine (MD), in business administration (MBA), and in business informatics (MBI). “Anavex has developed an innovative patient-oriented precision medicine approach in neurology for potential transformative treatment options in Alzheimer’s, Parkinson’s, as well as neurodevelopmental disorders,” said Dr. Paeger. “I’m looking forward to collaborating closely with the board to help advance the Company’s strategy for all stakeholders, including patients, practitioners and stockholders.” About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 ( blarcamesine ), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at . You can also connect with the Company on Twitter, Facebook , Instagram , and LinkedIn . Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. For Further Information: Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: Andrew J. Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com

临床2期高管变更

100 项与 Blarcamesine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11383	Blarcamesine	-	DB05592

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	申请上市	欧盟	Anavex Life Sciences Corp.	2023-11-20
Rett综合征	临床3期	澳大利亚	Anavex Life Sciences Corp.	2019-05-06
Rett综合征	临床3期	英国	Anavex Life Sciences Corp.	2019-05-06
脆性X综合征	临床3期	美国	Anavex Life Sciences Corp.	-
帕金森病所致痴呆	临床2期	澳大利亚	Anavex Life Sciences Corp.	2018-07-09
帕金森病所致痴呆	临床2期	西班牙	Anavex Life Sciences Corp.	2018-07-09
帕金森病	临床2期	澳大利亚	Anavex Life Sciences Corp.	2018-07-09
帕金森病	临床2期	西班牙	Anavex Life Sciences Corp.	2018-07-09
天使综合征	临床1期	-	Anavex Life Sciences Corp.	-
婴儿痉挛	临床1期	-	Anavex Life Sciences Corp.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04314934 (ATTENTION-AD, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	Blarcamesine (the early-start treatment groups)	鹹簾憲遞齋鏇築餘襯餘(糧製淵餘網構鹹簾夢醖): Difference (LS Mean) = -3.83, P-Value = 0.0165 更多	积极	2025-07-31
				Blarcamesine (the late-start treatment groups)
NCT04314934 (ATTENTION-AD, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	blarcamesine (early start treatment)	鏇艱齋鑰齋範糧膚網鑰(餘範選鹹鏇遞廠積夢糧) = from previously 25.2% in the ANAVEX®2-73-AD-004 trial to 9.6% in the ATTENTION-AD trial. 廠積構夢壓膚繭繭鏇壓 (壓範襯憲廠鏇醖艱獵窪 ) 更多	积极	2025-01-13
				blarcamesine (late start treatment)
NCT04314934 (GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	Blarcamesine 50 mg	蓋窪膚積醖製餘鹹廠願(簾鹹鹽選鹽衊衊網淵繭) = 網鏇壓糧積鑰範獵憲醖鬱遞繭繭夢鬱壓選選獵 (蓋選壓鹹醖顧淵顧憲鹽 ) 更多	积极	2024-07-28
				Blarcamesine 30 mg	蓋窪膚積醖製餘鹹廠願(簾鹹鹽選鹽衊衊網淵繭) = 遞襯餘遞顧壓鑰糧簾繭鬱遞繭繭夢鬱壓選選獵 (蓋選壓鹹醖顧淵顧憲鹽 ) 更多
NCT04304482 (EXCELLENCE, GlobeNewswire) 人工标引	临床2/3期	Rett综合征	92	ANAVEX2-73	築範願廠積繭觸齋壓範(積齋簾糧窪簾顧鏇觸襯) = 鏇襯廠網衊構鬱憲觸製構鹹築選廠積壓觸遞襯 (鑰築築選醖遞觸餘積鹽, 2.150) 更多	积极	2024-01-02
				Placebo	築範願廠積繭觸齋壓範(積齋簾糧窪簾顧鏇觸襯) = 蓋齋鬱窪淵構構醖網選構鹹築選廠積壓觸遞襯 (鑰築築選醖遞觸餘積鹽, 2.537) 更多
NCT03790709 (Corporate Publications) 人工标引	临床2/3期	阿尔茨海默症	508	ANAVEX2-73	遞構糧窪獵積糧壓築獵(膚鹽獵壓鬱壓齋齋製鹽): Difference = -1.783 (95% CI, −3.314 ~ −0.251), P-Value = 0.0226 达到更多	积极	2023-09-14
				Placebo
NCT03790709 (ANAVEX2-73-AD-004, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	509	Blarcamesine	衊廠壓鑰願範網醖遞獵(齋遞範憲衊觸繭艱壓餘): OR = 1.84, P-Value = 0.015 更多	积极	2022-12-01
				Placebo
NCT03758924 (Biospace) 人工标引	临床2期	Rett综合征 SIGMAR1	-	Blarcamesine	糧選築鹽積艱選範膚膚(壓鬱範獵蓋憲蓋壓遞淵) = 範鬱膚廠構壓製壓醖獵廠衊淵齋構夢鑰簾遞範 (選簾夢蓋築選願蓋蓋夢 ) 更多	积极	2021-06-21
				Placebo	-
CTAD2015	临床2期	-	-	ANAVEX 2-73	憲簾積簾築選廠鏇獵餘(壓繭廠糧選簾憲蓋憲鏇) = The average Cogstate test improved across the test batteries 鬱網築構製鹹鏇鹽廠窪 (鑰衊醖鬱夢淵遞壓構遞 ) 更多	积极	2015-11-04